Samuel Hellman Net Worth

The estimated Net Worth of Samuel Hellman is at least $815 Thousand dollars as of 1 November 2004. Samuel Hellman owns over 14,000 units of Varian Medical Systems stock worth over $260,261 and over the last 21 years Samuel sold VAR stock worth over $554,680.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Samuel Hellman VAR stock SEC Form 4 insiders trading

Samuel has made over 5 trades of the Varian Medical Systems stock since 2003, according to the Form 4 filled with the SEC. Most recently Samuel sold 14,000 units of VAR stock worth $554,680 on 1 November 2004.

The largest trade Samuel's ever made was selling 14,000 units of Varian Medical Systems stock on 1 November 2004 worth over $554,680. On average, Samuel trades about 2,391 units every 22 days since 2003. As of 1 November 2004 Samuel still owns at least 15,740 units of Varian Medical Systems stock.

You can see the complete history of Samuel Hellman stock trades at the bottom of the page.

What's Samuel Hellman's mailing address?

Samuel's mailing address filed with the SEC is , , , , .

Insiders trading at Varian Medical Systems

Over the last 22 years, insiders at Varian Medical Systems have traded over $57,574,967 worth of Varian Medical Systems stock and bought 500 units worth $22,595 . The most active insiders traders include Kent J Thiry, Timothy E Guertin, and Dow R Wilson. On average, Varian Medical Systems executives and independent directors trade stock every 11 days with the average trade being worth of $181,124. The most recent stock trade was executed by Jesse Michael Bruff on 1 March 2021, trading 6,499 units of VAR stock currently worth $1,142,589.

What does Varian Medical Systems do?

Complete history of Samuel Hellman stock trades at Varian Medical Systems

Varian Medical Systems executives and stock owners

Varian Medical Systems executives and other stock owners filed with the SEC include:

• Dow Wilson,
  Chief Executive Officer, Director
• Kolleen Kennedy,
  President - Proton Solutions Division and Chief Growth Officer
• Chris Toth,
  President, Chief Operating Officer
• R. Andrew Eckert,
  Independent Chairman of the Board
• Jeffrey Balser,
  Independent Director
• Judy Bruner,
  Independent Director
• Anat Ashkenazi,
  Independent Director
• Jean-Luc Butel,
  Independent Director
• Regina Dugan,
  Independent Director
• David Illingworth,
  Independent Director
• Phillip Febbo,
  Independent Director
• Michael Hutchinson,
  Senior Vice President, Chief Legal Officer
• Francis Facchini,
  President, Interventional Solutions Business
• Anshul Maheshwari,
  Vice President, Treasurer and Investor Relations
• Michelle Le Beau,
  Independent Director
• J. Michael Bruff,
  Chief Financial Officer, Senior Vice President - Finance
• Magnus Momsen,
  SVP, CAO, Corporate Controller
• Mark R Laret,
  Director
• Jose Baselga,
  Director
• John W Kuo,
  SVP, Gen Counsel and Secretary
• Gary E Jr Bischoping,
  SVP, Finance & CFO
• Susan L Bostrom,
  Director
• Timothy E Guertin,
  Director
• Clarence R Verhoef,
  SVP, Finance, Corp Controller
• Venkatraman Thyagarajan,
  Director
• Sunny Sanyal,
  SVP and President, ICB
• Robert H Kluge,
  Corporate Vice President
• Richard M Levy,
  President and CEO
• Ruediger Naumann Etienne,
  Director
• John Seely Brown,
  Director
• Erich R Reinhardt,
  Director
• Tai Yun Chen,
  VP and Corporate Controller
• David W Jr Martin,
  Director
• Steven A Leibel,
  Director
• Kent J Thiry,
  Director
• Allen S Lichter,
  Director
• Samuel Hellman,
  Director
• Crisanto C Raimundo,
  Corporate Controller
• Terry R Lautenbach,
  Director
• Joseph B Phair,
  VP Admin,Gen Counsel,Secretary
• Elisha W Finney,
  Corporate Vice President & CFO
• Kevin O'reilly,
  SVP, President of Oncology Sys